Harvey Capital Management Inc Aerie Pharmaceuticals Inc Transaction History

Harvey Capital Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Oct 17, 2019	SELL	$18.41 - $28.0 $412,384 - $627,200	-22,400 Closed	0 $0
Q2 2019 Jul 23, 2019	BUY	$28.97 - $48.21 $648,928 - $1.08 Million	22,400 New	22,400 $661,000
Q3 2018 Oct 24, 2018	SELL	$56.15 - $73.9 $422,528 - $556,097	-7,525 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$47.85 - $70.45 $765,312 - $1.13 Million	-15,994 Reduced 68.0%	7,525 $508,000
Q4 2017 Feb 02, 2018	SELL	$50.85 - $65.1 $65,138 - $83,393	-1,281 Reduced 5.17%	23,519 $1.41 Million
Q3 2017 Nov 08, 2017	BUY	$48.6 - $60.1 $1.21 Million - $1.49 Million	24,800	24,800 $1.21 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Harvey Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Harvey Capital Management Inc with notifications on news.